InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,221.42
(
-0.02%
)
US TECH 100
17,728.40
(
0.03%
)
Dow Jones
39,431.51
(
-0.21%
)
Brent Oil
82.92
(
-0.35%
)
Bitcoin
61,782.45
(
-1.78%
)
Post# of 3898
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

irule

Send PM Follow Ignore
Followers 0
Posts 86
Boards Moderated 0
Alias Born 08/29/2008

irule

Re: None

Friday, 06/15/2018 11:06:49 PM

Friday, June 15, 2018 11:06:49 PM

Post# of 3898
Imminent Q2 catalysts:

Completed data from Phase 2a trial of RX-3117 as 3rd line treatment of metastatic bladder cancer patients

Interim clinical data from Phase 2a trial of RX-5902 in triple negative breast cancer patients
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
InvestorsHub NewsWire

FEATURED Element79 Gold Corp Reports Exceptionally High-Grade Results from Lucero • May 14, 2024 7:00 AM

Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM

VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM

Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM

Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM

Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM

Start posting your company's news
Only $200 per official company press release!